PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surg…
Medical - Devices
US, Redwood City [HQ]
Ratios
5 Sheets · From 2023 to 2019Configuration
Margins, Growth Rates In %
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross Margin | -30.56 | -16.26 | 46.02 | 49.44 | 52.17 | |
| Profit Margin | -691.41 | -754.89 | -180.96 | -124.76 | -77.76 | |
| Operating Margin | -705.95 | -619.44 | -157.12 | -107.61 | -80.16 | |
|
EPS Growth
|
- - | -36.36 | -5.93 | -47.55 | -6.16 | |
| EPS USD | -99.00 | -135.00 | -143.00 | -211.00 | -224.00 | |
| Return on Assets (ROA) | -68.80 | -46.24 | -18.51 | -30.25 | -26.17 | |
| Return on Equity (ROE) | 29.65 | 31.85 | -23.36 | -47.49 | -37.72 | |
| Return on Invested Capital (ROIC) | 37.65 | 40.99 | -17.58 | -31.59 | -32.71 | |
| Solvency | ||||||
| Equity Ratio | -200 | -100 | - - | - - | - - | |
| Debt/Assets | 42.42 | 43.47 | 16.05 | 25.00 | 13.10 | |
| Debt/Equity | -18.28 | -29.94 | 20.26 | 39.23 | 18.89 | |
| Debt/EBITDA | 45.90 | 101.31 | 463.00 | 183.63 | 168.96 | |
|
Debt/Capitalization
|
-22.37 | -42.74 | 16.84 | 28.18 | 15.89 | |
| Long-Term Debt/Capitalization | -19.25 | -36.09 | 16.29 | 27.62 | 15.46 | |
| Interest Debt per Share USD | 0.62 | 1.39 | 1.37 | 1.86 | 1.21 | |
| Debt Growth | - - | 135.80 | -1.21 | 42.92 | 2.44 | |
| Liquidity | ||||||
| Current Ratio | 747.22 | 759.03 | 2,008.33 | 772.53 | 763.31 | |
| Quick Ratio | 635.05 | 699.98 | 1,901.26 | 671.95 | 665.40 | |
| Cash Ratio | 618.87 | 689.32 | 1,873.78 | 628.67 | 560.07 | |
| Operating Cash Flow Ratio | -600 | -300 | -300 | -200 | -200 | |
| Turnover | ||||||
| Inventory Turnover | 120.46 | 120.00 | 141.54 | 132.88 | 163.86 | |
| Receivables Turnover | 561.33 | 498.19 | 772.25 | 491.19 | 281.53 | |
| Payables Turnover | 557.76 | 723.55 | 917.10 | 403.89 | 482.57 | |
|
Asset Turnover
|
9.95 | 6.13 | 10.23 | 24.25 | 33.65 | |
| Fixed Turnover | 74.57 | 59.75 | 414.14 | 233.42 | 278.00 | |
| Coverage | ||||||
| Interest Coverage | -6,015.19 | -908.61 | -932.25 | -1,557.48 | -2,732.67 | |
| Asset Coverage | 200 | 200 | 500 | 300 | 400 | |
| Cash Flow Coverage (CFGR) | -166.64 | -88.28 | -105.98 | -103.96 | -203.69 | |
| EBITDA Coverage | -5,600 | -800 | -900 | -1,500 | -2,600 | |
| Dividend Coverage | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||
| Dividend Yield | - - | - - | - - | - - | - - | |
| Earnings Yield | -2.35 | -3.21 | -5.71 | -5.07 | -5.35 | |
|
Price/Earnings (P/E)
|
-4,252.99 | -3,113.94 | -1,750.99 | -1,970.82 | -1,870.17 | |
| Price/Earnings Growth (PEG) | - - | -85.63 | -295.48 | -41.45 | -303.54 | |
|
Price/Book (P/B)
|
-1,261.17 | -991.85 | 408.97 | 935.89 | 705.41 | |
| Price/Tangible Book (P/TB) | -1,261.17 | -991.85 | 408.97 | 935.89 | 705.41 | |
| Price/Sales (P/S) | 29,405.55 | 23,506.91 | 3,168.67 | 2,458.71 | 1,454.18 | |
|
Price/Cash Flow (P/CF)
|
-4,139.92 | -3,752.41 | -1,905.22 | -2,294.51 | -1,833.71 | |
| Price/Free CF (P/FCF) | -3,527.25 | -3,734.41 | -1,885.75 | -2,221.20 | -1,486.73 | |
| Price/Operating CF (P/OCF) | -4,139.92 | -3,752.41 | -1,905.22 | -2,294.51 | -1,833.71 |